logo-loader

Aerie Pharmaceuticals

Receive alerts
Market:
NASDAQ
Market Cap:
$1.04 billion
Price
22.50 USD
Change
1.81%
52 weeks high
50.06
52 weeks low
17.18

In brief

We are a publicly traded (NASDAQ: AERI), clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Glaucoma is one of the largest segments in the global ophthalmic market. In 2015, branded and generic glaucoma product sales exceeded $4.7 billion in the United States, Europe and Japan in aggregate, according to IMS. Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, resulting in irreversible vision loss and potentially blindness.